• Publications
  • Influence
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk
Background: Risk factors for multiple sclerosis (MS) include human leukocyte antigen (HLA)-DR and Epstein-Barr virus (EBV)-specific antibody responses, including an epitope within EBV nuclear antigenExpand
  • 13
  • 2
Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis
Background Epstein-Barr virus (EBV) infection represents a major environmental risk factor for multiple sclerosis (MS), with evidence of selective expansion of Epstein-Barr Nuclear Antigen-1Expand
  • 9
  • 1
  • PDF
The Combined Utility of Ex Vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions.
BACKGROUND For severe cutaneous adverse reactions (SCARs) associated with multiple antibiotics dosed concurrently, clinical causality is challenging and diagnostic approaches are limited, leading toExpand
  • 20
New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals.
Abacavir hypersensitivity syndrome (ABC HSS) is strongly associated with carriage of human leukocyte antigen (HLA)-B*57:01, which has a 100% negative predictive value for the development of ABC HSS.Expand
  • 3
Contribution of EBV infection to Multiple Sclerosis Pathogenesis: Human leukocyte antigen restricted, EBV epitope-specific T cell responses in Multiple Sclerosis
Multiple sclerosis (MS) is the most common chronic inflammatory disorder of the central nervous system in young adults and a prototypic autoimmune disease. Similar to other autoimmune diseases theExpand
  • 1
  • PDF
7th drug hypersensitivity meeting: part one
Table of contentsOral AbstractsO1 Functionally distinct HMGB1 isoforms correlate with physiological processes in drug-induced SJS/TENDaniel F. Carr, Wen-Hung Chung, Rosalind E. Jenkiins, MasExpand
  • 1
7th Drug hypersensitivity meeting: part two
Table of contentsPoster walk 11: miscellaneous drug hypersensitivity 2 (P92–P94, P96–P101)P92 16 years of experience with proton pump inhibitors (PPIs)Javier Dionicio Elera, Cosmin Boteanu, MariaExpand
  • 3
  • PDF